SECURE: Treatment With Polypill Significantly Lowers Risk of Major CV Events

Treatment with a polypill containing aspirin, ramipril and atorvastatin within six months after myocardial infarction (MI) resulted in a significantly lower risk of major adverse cardiovascular events compared with usual care, according to findings from the SECURE study presented during ESC Congress 2022 in Barcelona, and simultaneously published in the New England Journal of Medicine.

DELIVER: Dapagliflozin Lowered Risk of Worsening HF, Death in Patients With HFmrEF, HFpEF

Among patients with heart failure (HF) and a mildly reduced or preserved ejection fraction, dapagliflozin resulted in a lower risk of worsening HF or cardiovascular death compared with placebo, according to findings from the DELIVER trial. The results, presented at ESC Congress 2022 and simultaneously published in the New England Journal of Medicine, add to the evidence surrounding SGLT2 inhibitors in patients with a higher left ventricular ejection fraction (LVEF).

INVICTUS: Rivaroxaban vs. VKA Therapy in RHD-Associated AFib

Compared with rivaroxaban therapy, vitamin K antagonist (VKA) therapy in patients with rheumatic heart disease (RHD)-associated atrial fibrillation (AFib) was associated with a lower rate of cardiovascular events or death and no higher rate of bleeding, according to findings from the INVICTUS trial presented during ESC Congress 2022, and simultaneously published in the New England Journal of Medicine.